Elevance Health

ELV

400.7301.66% ( -6.770 )

Trading: Sep 8, 10:42:15 (EDT)

2026-W362026-08-31

ELV.US Weekly Report · 2026-W36

Elevance Health rose 3.81% this week, reaching a weekly high of 414.78 on Wednesday before a modest pullback on Thursday. Support comes from low valuation and sustained institutional bullishness, but Q2 earnings revealed a 16% year-over-year profit decline. Capital flows show both retail and large institutions withdrawing while mid-cap investors step in—a contradiction between cheap valuations and growth headwinds.

Price Action

Closing price of 407.50 reflects a 3.81% gain from the prior week’s close on August 31 (392.54). The week’s trading range showed modest volatility at 1.99% (high 414.46 vs. low 406.33), establishing an upward trend.

Day-by-day progression: September 1–3 recorded consecutive gains, with 9/1 rallying from 396.44 to 403.04 (+1.65%), 9/2 extending to 405.84, and 9/3 peaking at 414.78 (intraday high 416.58). On 9/4, the stock pulled back to 407.50. Volume for the week totaled approximately 1.13 million shares, positioning it at mid-range compared to the past 60 days (ranging from 700k to 3.9M shares). Turnover rate of 0.52% remains subdued, suggesting moderate investor engagement.

Valuation & Earnings

The P/E multiple of 17.81x sits at approximately the 23rd percentile over the past three years—a low valuation tier. Compared to the industry median of 25.48x, it trades 30% below peers and ranks favorably within managed healthcare. This discount may reflect cautious market expectations about growth prospects.

Q2 2026 results highlight growth deceleration: EPS of 6.71 dipped sequentially (Q1: 8.00) and fell 13.08% year-over-year. Operating revenue of 50.474 billion showed only 1.4% YoY growth, sharply decelerating from Q1’s 2.64%. Net profit of 1.463 billion declined 16.06% YoY, with the steeper profit decline versus revenue pointing to margin compression. ROE contracted from 16.08% (Q1) to 13.18% (Q2).

Consensus EPS forecast stands at 27.09 (median 27.04) on a forward basis. Against TTM EPS of 22.88, this implies expectations of H2 earnings recovery. However, Q2’s negative year-over-year momentum has yet to reverse.

Capital Flows & Institutional Sentiment

Capital flows reveal divergent behavior: large institutions net outflowed (inflow 32.50 vs. outflow 40.69, net -8.19), retail significantly withdrew (inflow 800.97 vs. outflow 1262.73, net -461.76), leaving only mid-cap funds stepping in (inflow 642.57 vs. outflow 526.62, net +115.95). This structure shows both retail and large money exiting while mid-sized capital absorbs supply.

Analyst coverage tilts bullish: 22 analysts with 12 strong buys, 3 buys, and 7 holds—zero reduces or sells. Target price of 449.09 implies 10.2% upside from current 407.50. Note that ratings last updated August 21, roughly two weeks prior; the Q2 profit decline has not yet triggered analyst downgrades.

Weekly News Roundup

This week’s narrative centers on whether the rebound sustains and valuation reappraisal in light of earnings headwinds.

Market commentary highlights that despite a 37% year-to-date rally, the stock remains viewed as undervalued relative to recent profit declines. Concurrently, major institutions including Jefferies, Vista Investment Management, and Mitsubishi UFJ Asset Management continued building positions or increasing stakes, signaling conviction in long-term value. Yet these institutional accumulations contrast with actual capital outflows, suggesting institutions may be buying dips rather than chasing higher.

Summary

This week’s price recovery reflects a tug-of-war between two forces: low valuation and institutional support on one side, offset by Q2’s 16% profit decline and dual-direction capital outflows on the other. Mid-cap fund absorption may represent selective institutional buying on weakness rather than broad market consensus. The critical watch ahead is whether H2 results reverse the YoY profit trajectory—a necessary condition to sustain the week’s gains and validate the low valuation.